Today, iCoat Medical welcomes Göran Lerenius as its General Counsel.
As iCoat Medical is progressing its ongoing First In Human-study, early preparations have commenced for the subsequent phase 2 study. This efficacy study will be an international multicenter study with presence in several countries. As part of this future development, iCoat Medical will need to increase its clinical team and legal capabilities in order to be prepared for the next phase.
“Göran brings extensive experience from the legal side of the pharmaceutical industry as well as contract and governance experience on an international level. I am very happy to welcome him as a member of iCoat Medical’s team and look forward to work with him in the future” says iCoat Medical’s CEO Peder Waern.
Göran brings substantial knowledge into iCoat Medical from his career, which includes having served +30 years at Astra AB and AstraZeneca AB as general counsel and head of AstraZeneca’s global Intellectual Property litigation team. Göran is also a special advisor for Healthcap AB and serves as the Chairman of the Board for PharmNovo AB.
Göran holds a law degree from Lund University.
For more information, please contact:
Peder Waern, CEO – iCoat Medical AB
E-mail: peder.waern@icoatmedical.com